Overview

Cyclic Vomiting Syndrome (CVS) is a disorder of gut-brain interaction (DGBI) characterized by recurrent, stereotypical episodes of intense nausea and vomiting separated by intervals of complete or near-complete wellness. Within the Rome IV classification (2016), pediatric CVS falls under the category of Functional Nausea and Vomiting Disorders (Category H1a) in children and adolescents. CVS is widely regarded as a migraine-equivalent or migraine-related condition, belonging to the childhood periodic syndromes that are commonly precursors of migraine.

Despite first being described in the medical literature over 130 years ago, CVS remains underrecognized, with affected children often experiencing years of symptoms, repeated emergency department visits, hospitalizations, and invasive investigations before the correct diagnosis is established. The Rome IV criteria provide a standardized, symptom-based diagnostic framework that enables clinicians to identify CVS on clinical grounds, reducing diagnostic delay and promoting timely, targeted management.

Historical Context and Nosological Evolution

CVS was first described by Samuel Gee in 1882, who reported a series of children with recurrent attacks of vomiting interspersed with periods of normal health. For the next century, the condition was intermittently recognized in the pediatric literature but lacked formal diagnostic criteria, leading to inconsistent diagnosis and a perception that CVS was rare.

The Rome classification system first codified CVS as a recognized functional gastrointestinal disorder in the Rome II criteria (1999). Rome III (2006) refined the diagnostic thresholds and clarified the distinction between CVS and other recurrent vomiting disorders. With Rome IV (2016), the terminology was updated from "functional gastrointestinal disorders" to "disorders of gut-brain interaction," and the CVS criteria were further adjusted. Key changes in the Rome IV pediatric CVS criteria include the specification that at least 3 episodes must have occurred in the prior year with at least 2 in the past 6 months, that episodes must be separated by at least 1 week, and that the criteria must have been fulfilled for the last 6 months with symptom onset at least 3 months before diagnosis. A supportive criterion acknowledging the migraine association (personal or family history of migraine headaches) was also formalized.

The International Headache Society (IHS) also recognizes CVS in the International Classification of Headache Disorders (ICHD-3) under "Episodic Syndromes That May Be Associated with Migraine." The Rome IV and ICHD-3 criteria are broadly harmonized but differ in some specifics, particularly regarding the minimum number of episodes required.

Epidemiology

CVS affects an estimated 0.3% to 2% of school-age children in population-based studies. Prevalence figures vary depending on the diagnostic criteria applied and the population studied. The condition can present at any age, from infancy to adolescence, with a mean age of onset typically reported between 3 and 7 years. Some studies have identified a bimodal age distribution, with peaks in early childhood (2-5 years) and early adolescence.

Sex distribution in pediatric CVS is approximately equal, with a slight female predominance in some series, contrasting with the more pronounced female predominance seen in adult CVS. Caucasian children appear to be disproportionately represented in published series, though it is unclear whether this reflects true population differences or ascertainment bias.

The delay from symptom onset to diagnosis remains unacceptably long. Studies report a mean diagnostic delay of 2 to 3 years, with some children experiencing symptoms for over 5 years before CVS is recognized. During this interval, children accumulate a significant burden of emergency department visits, hospitalizations, imaging studies, endoscopies, and missed school days. One frequently cited study found that children with CVS averaged 6 emergency department visits, 3 hospitalizations, and 20 missed school days per year before diagnosis.

A family history of migraine is present in 50% to 82% of children with CVS, one of the highest rates among all the childhood periodic syndromes. A family history of CVS itself, though less systematically studied, has also been reported, suggesting a strong genetic component.

Pathophysiology

CVS as a Migraine-Spectrum Disorder

The association between CVS and migraine is one of the most consistently replicated findings in the CVS literature. The evidence supporting this association includes the high prevalence of personal and family migraine history, the shared clinical features (episodicity, stereotypy, prodromal symptoms, trigger sensitivity), the common response to migraine-directed therapies, and the longitudinal progression from CVS in childhood to migraine headaches in adolescence and adulthood. The International Headache Society formally classifies CVS as an episodic syndrome that may be associated with migraine, reflecting this consensus.

The Gut-Brain Axis

CVS is a paradigmatic disorder of gut-brain interaction. The enteric nervous system and the central nervous system share neurotransmitter systems, and bidirectional signaling along the vagus nerve and the sympathetic trunk connects the brain to the gastrointestinal tract. In CVS, triggers activate a central cascade (hypothesized to involve the same brainstem nuclei implicated in migraine) that produces intense emetic signaling via vagal and central emetic pathways. The nucleus tractus solitarius, area postrema (chemoreceptor trigger zone), and dorsal motor nucleus of the vagus are key brainstem structures involved in the emetic reflex, and their activation during CVS episodes produces the violent, sustained vomiting that characterizes the condition.

Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

Stress is one of the most commonly identified triggers for CVS episodes, and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the pathogenesis. Elevated levels of corticotropin-releasing factor (CRF) and adrenocorticotropic hormone (ACTH) have been documented during CVS episodes. CRF acts on CRF receptors in the brain and gut to stimulate gastric stasis, intestinal motility alterations, and emetic signaling. Anxiety and psychological stress, both potent activators of the HPA axis, are among the most frequently reported episode triggers.

Autonomic Nervous System Dysfunction

Autonomic disturbance is a prominent feature of CVS. During episodes, children commonly exhibit signs of autonomic activation: pallor, diaphoresis, tachycardia, hypersalivation, and lethargy. Between episodes, subtle autonomic dysfunction may persist. Studies using heart rate variability analysis and tilt table testing have demonstrated altered sympathovagal balance in CVS patients, with evidence of both sympathetic hyperactivation and parasympathetic withdrawal. These autonomic features overlap with those seen in migraine and further link CVS to the migraine spectrum.

Mitochondrial Dysfunction

A subset of children with CVS, particularly those with early onset (before age 2 years), additional neurological features, or maternal inheritance patterns, may harbor mitochondrial DNA mutations. Mitochondrial dysfunction impairs cellular energy production and increases vulnerability to metabolic stress, which may lower the threshold for triggering CVS episodes. Specific mitochondrial DNA polymorphisms (e.g., 16519T and 3010A) have been found at significantly higher frequency in CVS patients compared to controls. This mitochondrial link has therapeutic implications, as coenzyme Q10 and L-carnitine supplementation (aimed at supporting mitochondrial function) have shown benefit in some CVS cohorts.

Serotonin and Neurotransmitter Dysregulation

Serotonin (5-HT) plays a central role in both migraine and emetic physiology. The vast majority of the body's serotonin resides in enterochromaffin cells of the gastrointestinal tract, where it modulates motility, secretion, and visceral sensation. Serotonin also acts on 5-HT3 receptors in the area postrema and vagal afferents to trigger the vomiting reflex. Dysregulation of serotonergic signaling has been implicated in CVS, and the efficacy of 5-HT3 receptor antagonists (ondansetron) in managing acute episodes further supports this mechanism. Catecholamine dysregulation, including elevated norepinephrine and epinephrine levels during episodes, has also been documented.

Calcitonin Gene-Related Peptide (CGRP)

CGRP, a neuropeptide central to migraine pathogenesis, is also expressed in enteric neurons and vagal afferents. While CGRP-targeted therapies (monoclonal antibodies and gepants) have transformed adult migraine treatment, their role in CVS is an area of active investigation. Preliminary case reports in adult CVS suggest potential benefit, though pediatric data remain limited.

Genetic Susceptibility

The familial clustering of CVS with migraine, the association with specific mitochondrial DNA polymorphisms, and emerging genome-wide association data all point to a significant genetic contribution. Candidate genes include those involved in ion channel function (implicated in migraine: CACNA1A, ATP1A2, SCN1A), serotonin metabolism, catecholamine signaling, and mitochondrial oxidative phosphorylation. The inheritance pattern is complex, likely polygenic with environmental modulation, though maternal (mitochondrial) inheritance has been specifically highlighted.

Rome IV Diagnostic Criteria

The diagnosis of child cyclic vomiting syndrome requires that all of the following required criteria are met. A supportive criterion (not required for diagnosis) further strengthens clinical confidence.

Required Criterion 1: Episode Frequency

The child must have experienced at least 3 discrete vomiting episodes within the prior 12 months, with at least 2 of those episodes occurring within the past 6 months. Episodes must be separated by a minimum of 1 week of symptom-free or symptom-reduced time. This frequency threshold ensures that the episodic pattern is well established and reproducible. The requirement for at least 1 week between episodes distinguishes CVS from conditions that produce daily or near-daily vomiting (e.g., gastroparesis, rumination disorder) and from closely spaced vomiting episodes that may represent a single prolonged episode rather than distinct cycles.

Required Criterion 2: Stereotypical Episodes

Each vomiting episode must follow a recognizable, consistent pattern for that individual child. Stereotypy refers to the reproducibility of multiple episode characteristics: the onset is acute (typically beginning in the early morning hours or upon waking, though this is not universal), the duration is less than 1 week, the peak intensity and vomiting frequency are similar from episode to episode, and the associated symptoms (nausea, pallor, lethargy, anorexia) follow a predictable pattern. Parents can typically describe the "typical attack" in considerable detail, often noting that episodes are nearly identical in their evolution. This stereotypy is a hallmark of CVS and reflects the reproducible activation of the same neurobiological cascade during each episode. Highly variable presentations, or episodes with inconsistent features, should prompt reconsideration of alternative diagnoses.

Required Criterion 3: Absence of Vomiting Between Episodes

Between vomiting episodes, the child returns to baseline health with no vomiting. This inter-episode wellness is a defining feature of CVS and distinguishes it from conditions producing chronic or continuous vomiting. The Rome IV criteria acknowledge that other milder symptoms may persist between cycles; children may experience inter-episode nausea, mild abdominal discomfort, fatigue, or appetite changes. However, active vomiting should not occur during inter-episode intervals. If vomiting is present between episodes, a "coalescent" pattern may be developing (see Special Considerations), or an alternative diagnosis should be pursued.

Required Criterion 4: Symptoms Not Attributable to Another Condition

After an appropriate medical evaluation, the symptoms cannot be attributed to another medical condition. This criterion mandates that organic, structural, metabolic, neurological, and other causes of recurrent vomiting have been reasonably excluded through a workup proportionate to the clinical presentation. The extent of investigation should be guided by the child's age, episode characteristics, and the presence or absence of alarm features. This criterion is discussed in detail in the Diagnostic Approach section.

Required Criterion 5: Temporal Requirement

The diagnostic criteria must have been fulfilled for the last 6 months, with the initial symptom onset occurring at least 3 months before the diagnosis is established. This temporal filter ensures that the episodic pattern is sustained and not merely a transient phenomenon. It also allows sufficient time for the recurrent pattern to emerge and be recognized.

Supportive Criterion: Personal or Family History of Migraine Headaches

A personal history of migraine or a family history of migraine in first-degree relatives is a supportive criterion that strengthens diagnostic confidence. This criterion is not required for diagnosis but is present in the majority of pediatric CVS cases (50-82% report a positive family history of migraine). The migraine association provides pathophysiological context and has practical implications: children with CVS and a migraine background are more likely to respond to migraine-directed prophylactic therapies.

Clinical Features and Presentation

The Four Phases of a CVS Episode

A CVS episode can be conceptualized as progressing through four phases, mirroring the temporal structure of a migraine attack:

• Prodromal Phase: Many children experience a recognizable prodrome in the minutes to hours before vomiting begins. Prodromal symptoms include pallor, nausea, abdominal pain, anorexia, lethargy, mood changes (irritability, withdrawal), diaphoresis, and occasionally headache. Parents who learn to recognize the prodrome can initiate abortive therapy during this window, potentially truncating or attenuating the episode.
• Emetic Phase: The emetic phase is characterized by intense, relentless nausea and vigorous vomiting. At peak intensity, children may vomit 6 to 12 times per hour or more. The vomiting may be bilious (due to retrograde duodenal contractions) and may contain blood (Mallory-Weiss tears from forceful retching). Children are typically pale, diaphoretic, tachycardic, and withdrawn. They may be unable to tolerate any oral intake and may become significantly dehydrated. The emetic phase typically lasts from several hours to several days, with most episodes resolving within 24 to 72 hours. Episodes lasting up to 1 week are within the Rome IV definition.
• Recovery Phase: Vomiting ceases, nausea subsides, and the child gradually regains appetite, energy, and color. Recovery may be abrupt (the child suddenly "turns a corner" and feels well) or gradual over hours to a day. Oral intake is progressively reintroduced.
• Inter-episode (Well) Phase: Between episodes, the child returns to baseline health and normal function. By definition, vomiting is absent during this phase. Milder symptoms (low-grade nausea, fatigue, mild abdominal discomfort) may persist in some children but should not significantly impair function.

Episode Characteristics

CVS episodes tend to begin in the early morning hours (between midnight and 6 AM) or upon awakening. This nocturnal or early-morning onset is reported in approximately 40% to 60% of pediatric cases and may relate to diurnal cortisol rhythms and HPA axis activation during the cortisol awakening response. The intensity of vomiting is characteristically severe: peak emesis rates of 4 to 12 episodes per hour have been documented, far exceeding the vomiting associated with typical gastroenteritis or other common causes.

Trigger Factors

Identifiable triggers are reported by the majority of families. Common triggers in pediatric CVS include:

• Psychological stress and emotional excitement: Both negative stress (anxiety, school examinations, family conflict) and positive excitement (birthdays, holidays, travel) can trigger episodes. The association with positive excitement is particularly characteristic of CVS and distinguishes it from purely anxiety-driven conditions.
• Infections: Upper respiratory infections, sinusitis, and other intercurrent illnesses are common triggers, possibly mediated by immune-inflammatory activation of the HPA axis.
• Physical exhaustion and sleep deprivation: Disruption of sleep patterns and physical overexertion are frequently reported.
• Fasting and missed meals: Prolonged fasting may trigger episodes through metabolic stress pathways.
• Travel and motion: Motion sickness, which is highly prevalent in CVS patients, may provoke episodes. Car journeys are a commonly reported trigger.
• Certain foods: Chocolate, cheese, monosodium glutamate (MSG), and caffeine have been implicated, paralleling migraine dietary triggers.
• Menstruation: In peri-pubertal and post-pubertal girls, episodes may cluster around the menstrual cycle (catamenial CVS).
• Hot weather and dehydration: Environmental heat stress is reported in some cohorts.

Associated Symptoms

Beyond nausea and vomiting, CVS episodes are accompanied by a constellation of associated symptoms that reflect autonomic, gastrointestinal, and central nervous system involvement:

• Abdominal pain (reported in up to 80% of episodes, typically diffuse or periumbilical)
• Pallor (a hallmark vasomotor feature)
• Lethargy and prostration (children are often immobilized during episodes)
• Diaphoresis
• Hypersalivation and drooling
• Headache (reinforcing the migraine connection)
• Photophobia and phonophobia
• Diarrhea (in some children, particularly during severe episodes)
• Low-grade fever (reported in a subset, likely mediated by the inflammatory component of the episode)

Comorbidities

Children with CVS have elevated rates of several comorbid conditions. Migraine headaches (either concurrent or developing during follow-up) are the most important comorbidity and are present in up to 40% of children at the time of CVS diagnosis, with an additional 30% to 40% developing migraine headaches during adolescent follow-up. Motion sickness is reported in up to 50% of children with CVS. Anxiety disorders, including generalized anxiety disorder and separation anxiety, are highly prevalent and may both trigger and be exacerbated by CVS episodes. Autonomic dysfunction, manifesting as orthostatic intolerance, postural tachycardia, or thermoregulatory instability, has been documented. Atopic disease (asthma, eczema, allergic rhinitis) is overrepresented in some CVS cohorts.

Differential Diagnosis

The differential diagnosis of recurrent episodic vomiting in children is broad and encompasses organic, structural, metabolic, neurological, and functional conditions. A systematic approach is essential:

• Gastrointestinal Conditions:
  • Malrotation with intermittent volvulus: Paroxysmal vomiting (often bilious) with abdominal pain. This is a surgical emergency if complete. An upper GI series is the diagnostic study of choice. Bilious vomiting in a child should always prompt consideration of malrotation.
  • Intermittent small bowel obstruction (adhesions, Meckel diverticulum, intussusception): May produce episodic vomiting and pain. Imaging during an episode is key.
  • Peptic ulcer disease and H. pylori gastritis: Recurrent vomiting and epigastric pain related to meals. Endoscopy and H. pylori testing can clarify.
  • Eosinophilic esophagitis or gastroenteritis: May produce recurrent vomiting, dysphagia, and abdominal pain. Endoscopy with biopsies is diagnostic.
  • Gastroparesis: Chronic or episodic nausea and vomiting with delayed gastric emptying. Gastric scintigraphy confirms the diagnosis. Unlike CVS, gastroparesis tends to produce more continuous symptoms without the well-defined episode-free intervals.
  • Chronic pancreatitis: Recurrent epigastric pain radiating to the back with nausea and vomiting. Serum lipase and pancreatic imaging are helpful.
  • Superior mesenteric artery (SMA) syndrome: Compression of the duodenum between the SMA and the aorta, particularly in thin individuals. Postprandial vomiting, often bilious. CT angiography or upper GI series can demonstrate the narrowed aortomesenteric angle.
• Neurological Conditions:
  • Posterior fossa tumors and other CNS neoplasms: Increased intracranial pressure can produce recurrent or progressive vomiting, often in the morning and accompanied by headache and visual changes. Brain MRI should be obtained if neurological red flags are present.
  • Chiari malformation: May cause recurrent vomiting, headache, and posterior fossa symptoms. Brain MRI with sagittal views through the craniocervical junction is diagnostic.
  • Hydrocephalus (especially intermittent shunt malfunction in children with VP shunts): Recurrent episodes of vomiting, headache, and altered sensorium may indicate shunt obstruction.
  • Abdominal epilepsy: Rare. Paroxysmal abdominal symptoms arising from seizure activity. EEG abnormalities and response to antiepileptic drugs distinguish this entity.
• Metabolic and Endocrine Conditions:
  • Inborn errors of metabolism: Disorders of fatty acid oxidation (MCAD, VLCAD, LCHAD deficiency), urea cycle defects, organic acidemias, and mitochondrial disorders can present with episodic vomiting, particularly triggered by fasting or intercurrent illness. These conditions are especially important to consider in children with early onset (before age 2), developmental delay, neurological features, hepatomegaly, or metabolic acidosis during episodes. Acylcarnitine profile, urine organic acids, ammonia, lactate, and pyruvate are key screening tests.
  • Diabetic ketoacidosis: Recurrent vomiting with polyuria, polydipsia, and weight loss. Blood glucose and ketone measurement are essential.
  • Addisonian crisis: Vomiting, dehydration, and hemodynamic instability in the context of adrenal insufficiency. Cortisol and ACTH levels are diagnostic.
  • Pheochromocytoma/paraganglioma: Rare in children but can produce episodic vomiting with hypertension, diaphoresis, and tachycardia. Plasma free metanephrines or 24-hour urine catecholamines are screening tests.
• Renal Conditions:
  • Ureteropelvic junction obstruction: Intermittent hydronephrosis can produce episodic flank or abdominal pain with vomiting. Renal ultrasound during an episode may be revealing.
  • Nephrolithiasis: Paroxysmal flank pain with nausea and vomiting. Urinalysis and renal imaging can clarify.
• Other Functional/Migraine-Related Conditions:
  • Abdominal migraine: Also a migraine-spectrum DGBI in children. The distinguishing feature is that abdominal pain (not vomiting) is the most severe and distressing symptom. Nausea and vomiting may be present but are secondary to the pain.
  • Rumination disorder: Repetitive, effortless regurgitation of recently ingested food that is re-chewed, re-swallowed, or expelled. Unlike CVS, rumination is not episodic, does not involve intense nausea, and occurs during or shortly after meals.
  • Functional nausea: Chronic, bothersome nausea without episodic vomiting. Distinguished from CVS by the absence of discrete vomiting episodes and inter-episode wellness.

Diagnostic Approach

Clinical History

The diagnosis of CVS is fundamentally clinical. A detailed history should characterize the episodic pattern: the number of episodes, their frequency, the duration of each episode, the interval between episodes, and whether the child returns to baseline between events. Stereotypy should be assessed by asking the family to describe a "typical episode" in detail, including time of onset, progression, peak intensity, associated symptoms, and recovery. Trigger factors, prodromal symptoms, and family history (particularly of migraine, CVS, or motion sickness) should be systematically elicited.

Alarm Features Warranting Urgent Investigation

The following features are not typical of CVS and should prompt immediate further evaluation:

• Bilious (green) vomiting, which raises concern for intestinal obstruction or malrotation
• Hematemesis (beyond minor streaks from retching), raising concern for peptic disease or vascular anomalies
• Progressive worsening of episodes in severity or frequency without inter-episode improvement
• Neurological signs: papilledema, focal deficits, altered mental status, ataxia
• Severe headache, particularly if new or changing in character
• Onset before age 2 years (higher index of suspicion for metabolic and structural conditions)
• Failure to thrive or significant weight loss
• Hepatomegaly, splenomegaly, or jaundice
• Metabolic acidosis, hypoglycemia, hyperammonemia, or lactic acidosis during episodes
• Consistent triggering by fasting (suggesting fatty acid oxidation or glycogen storage disorders)
• Abnormal developmental milestones or regression

Laboratory and Imaging Studies

There is no specific biomarker for CVS. The workup is directed at excluding alternative diagnoses. A reasonable tiered approach includes:

• Baseline studies (for most patients): Complete blood count, comprehensive metabolic panel, serum lipase, urinalysis, and celiac serologies (tissue transglutaminase IgA with total IgA).
• Metabolic screening (for early-onset, atypical, or severe cases): Serum ammonia, lactate, pyruvate, acylcarnitine profile (plasma), urine organic acids, and urine amino acids. These tests are most informative when obtained during or immediately after an acute episode.
• Neuroimaging: Brain MRI should be obtained if there are neurological symptoms, progressive headache, papilledema, or other CNS red flags.
• Upper GI series: An upper GI contrast study should be considered to exclude malrotation, particularly in younger children or those with bilious vomiting.
• Endoscopy: Upper endoscopy with biopsies may be indicated if there is suspicion for eosinophilic gastrointestinal disease, peptic ulcer disease, or mucosal pathology. It should not be performed routinely in all CVS patients without specific clinical indications.
• Gastric emptying study: Gastric scintigraphy may be helpful if gastroparesis is suspected (particularly if symptoms are more continuous than episodic).

The Positive Diagnostic Approach

The Rome Foundation strongly advocates making the diagnosis of CVS positively on the basis of the characteristic episodic pattern rather than treating it purely as a diagnosis of exclusion. The combination of stereotypical, recurrent vomiting episodes with inter-episode wellness, a positive migraine family history, identifiable triggers, and the absence of alarm features constitutes a highly recognizable clinical syndrome. Communicating the diagnosis confidently to the family, providing education about the condition, and initiating management without waiting for exhaustive exclusionary testing can dramatically reduce diagnostic delay and its associated morbidity.

Management

General Principles

Management of pediatric CVS is organized around four pillars: lifestyle modification and trigger avoidance, abortive (acute) therapy, prophylactic (preventive) therapy, and supportive care during episodes. The approach should be individualized based on episode frequency, severity, duration, identified triggers, comorbidities, and the child's developmental stage. A collaborative, empathic relationship with the family is foundational.

Lifestyle Modification and Trigger Avoidance

Identifying and mitigating known triggers can reduce episode frequency. Practical strategies include:

• Maintaining regular sleep schedules with adequate sleep duration
• Avoiding prolonged fasting; ensuring regular meals and snacks
• Adequate hydration, especially during physical activity and hot weather
• Stress management through relaxation training, guided imagery, or age-appropriate mindfulness exercises
• Avoiding known dietary triggers (chocolate, cheese, caffeine, MSG) where a consistent pattern is identified
• Managing motion sickness with positioning, visual fixation techniques, or pre-treatment with anti-motion-sickness agents before travel
• Anticipatory planning around known high-risk situations (e.g., pre-treating before events known to trigger excitement-related episodes)

Abortive (Acute) Therapy

Abortive therapy is most effective when initiated during the prodromal phase, before emesis is fully established:

• Ondansetron: A 5-HT3 receptor antagonist that is the first-line abortive agent in pediatric CVS. It can be administered orally (if tolerated), orally disintegrating tablet (ODT), or intravenously during the prodrome or early emetic phase. Dosing is typically 0.3 to 0.4 mg/kg per dose (max 16 mg) for IV administration. Ondansetron reduces nausea and vomiting intensity but may not abort the episode entirely.
• Triptans: Sumatriptan (intranasal 5-20 mg, or subcutaneous 3-6 mg in adolescents) may be effective as abortive therapy given the migraine-related pathophysiology. Triptans are most effective when given early in the prodrome. Use is off-label in younger children and should be guided by age-appropriate prescribing.
• NSAIDs: Ibuprofen or naproxen, administered during the prodrome, may provide adjunctive benefit, particularly when headache or abdominal pain is a prominent prodromal feature.
• Lorazepam: A benzodiazepine that provides anxiolysis, sedation, and has some antiemetic effect. Low-dose sublingual or IV lorazepam (0.05-0.1 mg/kg) can be useful during the early phase of an episode, particularly when anxiety and agitation are prominent. It should be used judiciously due to sedation and potential for habituation.

Supportive Care During Acute Episodes

Once a full emetic episode is established and oral intake is not tolerated, supportive care becomes the priority:

• Intravenous fluid resuscitation: Isotonic crystalloid (normal saline or lactated Ringer solution) with dextrose supplementation is the cornerstone of emergency management. Many children present with significant dehydration, electrolyte disturbances (hypokalemia, hypochloremic metabolic alkalosis), and hypoglycemia.
• IV ondansetron: Continued IV ondansetron for nausea and vomiting control.
• Pain management: Ketorolac (IV NSAID) for abdominal pain. Opioid analgesics should be used with extreme caution, as chronic opioid exposure can paradoxically increase CVS episode frequency and severity.
• Dark, quiet environment: Minimizing sensory stimulation (lights, noise, activity) during the emetic phase, analogous to migraine management.
• Monitoring: Electrolyte monitoring, glucose checks, and clinical assessment for complications (Mallory-Weiss tears, aspiration, pancreatitis from retching).

Prophylactic (Preventive) Therapy

Prophylaxis should be considered when episodes are frequent (more than 1 per month or more than 4 per year), prolonged, severe enough to require emergency department visits or hospitalization, or significantly impacting school attendance and quality of life:

• Cyproheptadine: A serotonin and histamine antagonist that is considered first-line prophylaxis for children under 5 years of age. Dosing is typically 0.25 to 0.5 mg/kg/day divided twice daily. Appetite stimulation and weight gain are common side effects. Sedation is usually transient.
• Amitriptyline: A tricyclic antidepressant with neuromodulatory and anti-migraine properties. It is considered first-line prophylaxis for children 5 years and older. Starting dose is 0.25 to 0.5 mg/kg at bedtime, titrated gradually up to 1 to 1.5 mg/kg/day (typical effective dose range 10-30 mg in younger children, up to 50-75 mg in adolescents). An ECG may be obtained before initiation and after dose adjustments to monitor the QTc interval. Side effects include sedation, dry mouth, constipation, and behavioral changes.
• Propranolol: A non-selective beta-blocker with established anti-migraine prophylactic efficacy. Used at 0.5 to 2 mg/kg/day divided twice or three times daily. Contraindicated in children with asthma or significant bradycardia. Particularly useful when comorbid anxiety is prominent.
• Topiramate: An anticonvulsant with migraine prophylaxis efficacy. Dosing starts at 1 mg/kg/day and is titrated up to 3-5 mg/kg/day. Side effects include cognitive dulling, weight loss, paresthesias, and metabolic acidosis. Generally reserved for refractory cases.
• Coenzyme Q10 and L-Carnitine: Mitochondrial cofactor supplementation is a low-risk adjunctive strategy with theoretical support from the mitochondrial dysfunction hypothesis. Coenzyme Q10 is typically dosed at 10 mg/kg/day (up to 200-400 mg/day) and L-carnitine at 50-100 mg/kg/day (up to 1-2 g/day). Evidence is limited to case series, but the favorable safety profile supports a trial, particularly in children with early-onset CVS or suspected mitochondrial predisposition.

Psychological and Behavioral Therapies

Cognitive behavioral therapy (CBT) targeting stress management, coping skills, and anxiety reduction is an important adjunct, particularly for children in whom psychological stress is an identified trigger. Biofeedback, relaxation training, and guided imagery have been used with benefit in case series. Family-based therapy addressing the impact of CVS on family dynamics, parental anxiety, and sibling relationships can also be valuable.

Complications

CVS episodes can produce significant acute and chronic complications:

• Dehydration and electrolyte disturbance: The most common acute complication. Severe episodes can produce hypovolemia, hypokalemic hypochloremic metabolic alkalosis, and hypoglycemia requiring IV resuscitation.
• Mallory-Weiss tears: Forceful retching can produce mucosal tears at the gastroesophageal junction, leading to hematemesis. This is usually self-limited but can be alarming.
• Aspiration: Particularly a risk in obtunded or heavily sedated children during active vomiting.
• Esophagitis and dental erosion: Recurrent exposure to gastric acid can damage the esophageal mucosa and dental enamel over time.
• Nutritional compromise and growth failure: Children with frequent, prolonged episodes may develop caloric deficits, weight loss, and impaired linear growth.
• Psychosocial morbidity: Missed school days, social isolation, anxiety, depression, and impaired quality of life are among the most significant long-term consequences. The unpredictability of episodes generates anticipatory anxiety in both the child and the family.
• Iatrogenic harm: Before diagnosis, children with CVS may accumulate unnecessary surgical procedures (appendectomy, cholecystectomy, Nissen fundoplication), excessive radiation exposure from repeated imaging, and chronic opioid exposure, all of which carry their own risks.

Prognosis and Natural History

The natural history of pediatric CVS is variable. Prospective and retrospective follow-up studies report the following general patterns:

• Approximately 50% to 60% of children experience resolution of CVS episodes by late childhood or early adolescence, typically within 2 to 5 years of diagnosis.
• An estimated 25% to 35% of children continue to have CVS episodes into adolescence and, in some cases, adulthood.
• Up to 70% of children with CVS develop migraine headaches during adolescence or adulthood, supporting the classification of CVS as a migraine precursor.
• A subset of children develop a "coalescent" pattern over time, in which the discrete episodic pattern gives way to more frequent or continuous nausea and vomiting, sometimes evolving into chronic nausea without discrete episodes. This coalescent pattern may be associated with poorer outcomes and requires reassessment of the treatment approach.

Prognostic factors associated with better outcomes include early diagnosis (reducing diagnostic delay and iatrogenic harm), effective prophylaxis with reduced episode frequency, strong family understanding of the condition, identification and avoidance of triggers, absence of chronic opioid use, and engagement with psychological therapies for comorbid anxiety. Poorer outcomes are associated with late diagnosis, frequent emergency visits and hospitalizations, chronic opioid exposure, severe psychiatric comorbidity, and the development of a coalescent pattern.

Special Considerations

CVS vs. Abdominal Migraine

CVS and abdominal migraine are both migraine-spectrum DGBIs in children, and distinguishing them is a common clinical challenge. The Rome IV criteria draw the distinction based on the predominant symptom:

• In CVS, intense nausea and vomiting are the most severe and distressing symptoms. Abdominal pain may accompany but does not overshadow the emesis.
• In abdominal migraine, paroxysmal abdominal pain is the most severe and distressing symptom. Nausea and vomiting may be present but are secondary to the pain.

Some children exhibit features of both conditions, and the predominant symptom may shift over time. Diagnostic overlap is explicitly acknowledged in the Rome IV literature, and the clinical response to migraine-directed therapies supports the shared underlying pathophysiology.

CVS in Infants and Young Children

CVS presenting before age 2 years warrants heightened vigilance for underlying metabolic disorders, particularly mitochondrial disease, fatty acid oxidation defects, and urea cycle disorders. The threshold for metabolic screening should be lower in this age group. Episodes triggered by fasting, intercurrent illness, or high-protein meals are particularly suggestive of metabolic etiology. Mitochondrial DNA testing may be indicated.

Cannabinoid Use in Adolescents

In adolescents, the rising prevalence of cannabis use has led to increasing recognition of cannabinoid hyperemesis syndrome (CHS), which can closely mimic CVS. CHS is characterized by cyclical vomiting in the setting of chronic, regular cannabis use, with a pathognomonic feature of compulsive hot bathing or showering for symptom relief. Confidential screening for cannabis use (including synthetic cannabinoids) should be performed in all adolescents presenting with a CVS-like picture. CHS resolves with sustained cannabis cessation.

Overlap with Other Pediatric DGBIs

A child may simultaneously meet criteria for CVS and another DGBI, such as functional abdominal pain-not otherwise specified (FAP-NOS) or irritable bowel syndrome (IBS). Dual diagnoses are permitted under the Rome IV framework. Treatment should address the specific symptom drivers of each co-existing condition.

The Coalescent Pattern

In some children, the classic episodic CVS pattern evolves into a coalescent pattern with increasingly frequent episodes, shorter inter-episode intervals, persistent inter-episode nausea, and eventually a more chronic, continuous symptom profile. This evolution may represent progression along the DGBI spectrum (potentially toward chronic nausea and vomiting disorder) and requires reassessment of the treatment plan. Escalation of prophylactic therapy, reassessment for emerging organic pathology, and intensification of psychological support are warranted.

Key Clinical Pearls

• CVS is a migraine-spectrum disorder characterized by recurrent, stereotypical episodes of intense vomiting with complete inter-episode wellness.
• The Rome IV criteria require at least 3 episodes in the prior year with at least 2 in the past 6 months, separated by at least 1 week, with stereotypical onset and duration less than 1 week.
• A personal or family history of migraine (present in 50-82% of cases) is a supportive criterion that strengthens diagnostic confidence but is not required.
• The four-phase model (prodrome, emetic, recovery, well interval) mirrors the migraine temporal structure and guides therapeutic timing.
• Early intervention during the prodrome with ondansetron and/or triptans can truncate or attenuate episodes.
• First-line prophylaxis is cyproheptadine for children under 5 and amitriptyline for children 5 and older.
• Coenzyme Q10 and L-carnitine supplementation is a low-risk adjunctive strategy supported by the mitochondrial dysfunction hypothesis.
• Bilious vomiting should always prompt exclusion of malrotation, regardless of the suspected CVS diagnosis.
• Early-onset CVS (before age 2) warrants metabolic screening for inborn errors of metabolism, particularly mitochondrial disease and fatty acid oxidation defects.
• In adolescents, cannabinoid hyperemesis syndrome must be excluded through confidential screening for cannabis use.
• Opioid analgesics should be used with extreme caution; chronic opioid use can worsen CVS frequency and severity.
• The mean diagnostic delay of 2-3 years highlights the importance of clinician awareness and a positive diagnostic approach based on the characteristic clinical pattern.

Calculator Interpretation Guide

This calculator evaluates whether a pediatric patient meets the Rome IV diagnostic criteria for Child Cyclic Vomiting Syndrome by assessing each of the 5 mandatory criteria. It also records the supportive criterion (personal or family history of migraine) for additional clinical context.

• All required criteria met (Positive): The patient's presentation is consistent with the Rome IV diagnosis of Child Cyclic Vomiting Syndrome, provided the temporal requirement is satisfied (symptoms present for at least 6 months with onset at least 3 months prior). If the supportive criterion (migraine history) is also positive, it further reinforces the diagnosis. Clinical correlation is essential, and appropriate exclusion of organic causes (metabolic, CNS, structural GI) must be ensured.
• One or more required criteria not met (Negative): The patient does not fulfill the Rome IV criteria for Child CVS. The specific unmet criteria should guide further evaluation. Alternative diagnoses to consider include gastroparesis, CNS disorders, metabolic conditions, malrotation, abdominal migraine, rumination disorder, and (in adolescents) cannabinoid hyperemesis syndrome.

This tool is intended for educational and clinical decision-support purposes only. It does not constitute medical advice and should not be used as the sole basis for clinical decisions. Always integrate the calculator result with the complete clinical picture and professional judgment.